Literature DB >> 1852013

Pharmacology and clinical perspectives of vasopressin antagonists.

F A László1, F László, D De Wied.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1852013

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN： 0031-6997            Impact factor:   25.468


× No keyword cloud information.
  23 in total

1.  Cerebral vasoconstriction produced by vasopressin in conscious goats: role of vasopressin V(1) and V(2) receptors and nitric oxide.

Authors:  N Fernández; M A Martínez; A L García-Villalón; L Monge; G Diéguez
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

2.  Characterization of a novel nonpeptide vasopressin V(2)-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes.

Authors:  S Nakamura; Y Yamamura; S Itoh; T Hirano; K Tsujimae; M Aoyama; K Kondo; H Ogawa; T Shinohara; K Kan; Y Tanada; S Teramoto; T Sumida; S Nakayama; K Sekiguchi; T Kambe; G Tsujimoto; T Mori; M Tominaga
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

3.  Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells.

Authors:  J Tsukada; A Tahara; Y Tomura; T Kusayama; N Ishii; T Yatsu; W Uchida; N Taniguchi; A Tanaka
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

4.  V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity.

Authors:  Taka-aki Koshimizu; Yoshihisa Nasa; Akito Tanoue; Ryo Oikawa; Yuji Kawahara; Yasushi Kiyono; Tetsuya Adachi; Toshiki Tanaka; Tomoyuki Kuwaki; Toyoki Mori; Satoshi Takeo; Hitoshi Okamura; Gozoh Tsujimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-08       Impact factor: 11.205

Review 5.  Role of vasopressin in the management of septic shock.

Authors:  Gökhan M Mutlu; Phillip Factor
Journal:  Intensive Care Med       Date:  2004-04-21       Impact factor: 17.440

6.  Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist.

Authors:  Y Yamamura; H Ogawa; H Yamashita; T Chihara; H Miyamoto; S Nakamura; T Onogawa; T Yamashita; T Hosokawa; T Mori
Journal:  Br J Pharmacol       Date:  1992-04       Impact factor: 8.739

7.  Oxytocin receptors expressed and coupled to Ca2+ signalling in a human vascular smooth muscle cell line.

Authors:  H Yazawa; A Hirasawa; K Horie; Y Saita; E Iida; K Honda; G Tsujimoto
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

8.  Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors.

Authors:  C Serradeil-Le Gal; J Wagnon; C Garcia; C Lacour; P Guiraudou; B Christophe; G Villanova; D Nisato; J P Maffrand; G Le Fur
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

9.  Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock.

Authors:  Andrea Morelli; Monica Rocco; Giorgio Conti; Alessandra Orecchioni; Andrea De Gaetano; Giuliana Cortese; Flaminia Coluzzi; Enrico Vernaglione; Paolo Pelaia; Paolo Pietropaoli
Journal:  Intensive Care Med       Date:  2003-12-12       Impact factor: 17.440

10.  Oxytocin receptors in the primate ovary: molecular identity and link to apoptosis in human granulosa cells.

Authors:  S Saller; L Kunz; G A Dissen; R Stouffer; S R Ojeda; D Berg; U Berg; A Mayerhofer
Journal:  Hum Reprod       Date:  2010-01-23       Impact factor: 6.918
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.